NCT05861778View on ClinicalTrials.gov

Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

November 27, 2023

Study Completion Date

November 27, 2023

Conditions
Clear Cell Renal Cell CarcinomaSuspected Recurrent Renal Clear Cell CarcinomaRecurrent Renal Cell Cancer
Interventions
DRUG

89Zr-Girentuximab

A single administration of 37 MBq (±10%) 89Zr-TLX250, containing a mass dose of 10 mg of girentuximab, followed by whole body PET/CT scans were performed at 0.5h, 4h, 24h, 72 hours and 7±1 days post administration.

Trial Locations (1)

Unknown

Peking University Cancer Hospital & Institute, Beijing

All Listed Sponsors
collaborator

Grand Pharmaceutical (China) Co., Ltd.

OTHER

lead

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY

NCT05861778 - Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma | Biotech Hunter | Biotech Hunter